GEN Exclusives

More »

GEN News Highlights

More »
Feb 27, 2012

BioConnections Licenses Hebrew University’s Rapid MDR Infection Test Kits

  • U.K microbiology products and services specialist BioConnections negotiated a licensing agreement with the Hebrew University of Jerusalem’s R&D and technology transfer arm, Yissum, to commercialize kits for the direct detection of any multidrug-resistant (MDR) and extremely drug resistant (XDR) infection in samples of patient urine or blood. BioConnections says the first kits are in the final stages of development, and are expected to reach the market within months. An application for CE mark approval in Europe is also in progress.

    The technology underlying the kits has been developed by the University Faculty of Medicine’s professor Emeritus Nathan Citri, M.D. The approach provides a direct indication of bacterial resistance to all beta-lactam antibiotics by detecting the presence of beta-lactamase enzymes that are produced by MDR bacteria. The modular kits comprise disposable arrays of antibiotics, in a combination that can be customized. Unprocessed samples are then placed on the array spots, and covered with a lid containing an indicator, which rapidly changes color in the presence of antibiotic-resistant organisms.

    “Currently available techniques for identifying drug resistant bacteria are slow or hardly accessible, and evidence-based decisions are delayed for days,” remarks Yaacov Michlin, Yissum CEO. “Professor Citri’s invention now enables hospitals to identify drug-resistant infections within minutes, so that the patient can immediately benefit from appropriate, evidence-based treatment while contagion and contamination are minimized.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?